IL17A and psoriasis: The beneficial effects of apremilast on clinimetric scores correlated in our study population with a significant decrease in serum levels of IL-17A, and TGF-β 1, which have proven to be higher in individuals with psoriasis in comparison to healthy controls (52, 53), although no statistical correlation has been found between IL-17 concentrations and PASI/NAPSI scores (54, 55).